| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026001 | Ophthalmology | 2015 | 10 Pages |
Abstract
No safety concerns were identified after systemic administration of AKB-9778 for 4 weeks in patients with DME, and doses of 15 mg or more twice daily reduced macular edema and improved vision in some patients. This is a preliminary demonstration of clinical safety and efficacy of a VE-PTP inhibitor and Tie2 activator.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter A. MD, Raafay MD, Michael MD, Daniel M. MD, PhD, David MD, David S. MD, Jeffrey S. MD, Laura BS, Barbara PhD, Mitchell PhD, Kevin MD,